Skip to NavigationSkip to content

Sanofi's Toujeo proves non-inferior to insulin degludec in type 2 diabetes

Published on 26/06/18 at 11:06am

Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on its diabetes therapy Toujeo (insulin glargine 300 units.mL), demonstrating that it proved non-inferior to insulin degludec in adult patients with type 2 diabetes who were not previously on insulin.

Toujeo met its primary endpoint in the almost-1,000-strong study, proving to be as effective as insulin degludec in reducing HbA1 levels, while it also proved potent in reducing the rate of ‘anytime hypoglycaemia’ in the sensitive first 12 weeks. During this key period, Toujeo was shown to lower the confirmed incidence of hypoglycaemia by 26% compared to its comparator.

Over the full 24 weeks of the study, both therapies were proven to be comparable in incidence of hypoglycaemia, recorded at 66.5% with Toujeo and 69% with insulin degludec.

“Hypoglycaemia is a concern for people with diabetes mainly in the initial period of dose adjustment and can lead to poor medium-term blood sugar control or discontinuation of treatment,” commented Professor Jeffrey Stephens, Clinical Professor of Diabetes at Swansea University. “These promising results add reassurance to both patients and healthcare professionals during the critical early treatment period and provide further confidence for controlling their blood sugar in the future.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches